Cargando…
The Care of the Leukemic Patients in Times of SARS-CoV-2
PURPOSE OF REVIEW: The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe infection and increased rates of mortality. There is paucity of informat...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330191/ https://www.ncbi.nlm.nih.gov/pubmed/34342734 http://dx.doi.org/10.1007/s11912-021-01111-0 |
_version_ | 1783732653095124992 |
---|---|
author | Karki, Nabin Raj Le, Thuy Cortes, Jorge |
author_facet | Karki, Nabin Raj Le, Thuy Cortes, Jorge |
author_sort | Karki, Nabin Raj |
collection | PubMed |
description | PURPOSE OF REVIEW: The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe infection and increased rates of mortality. There is paucity of information on how to modify care of leukemia patients in view of the COVID-19 risks and imposed restrictions. We review the available literature on the impact of COVID-19 on different types of leukemia patients and suggest general as well as disease-specific recommendations on care based on available evidence. RECENT FINDINGS: The COVID-19 infection impacts leukemia subtypes in variable ways and the standard treatments for leukemia have similarly, varying effects on the course of COVID-19 infection. Useful treatment strategies include deferring treatment when possible, use of less intensive regimens, outpatient targeted oral agents requiring minimal monitoring, and prioritization of curative or life-prolonging strategies. Reducing health care encounters, rational transfusion standards, just resource allocation, and pre-emptive advance care planning will serve the interests of leukemia patients. SUMMARY: Ad hoc modifications based on expert opinions and extrapolations of previous well-designed studies are the way forward to navigate the crisis. This should be supplanted with more rigorous prospective evidence. |
format | Online Article Text |
id | pubmed-8330191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-83301912021-08-04 The Care of the Leukemic Patients in Times of SARS-CoV-2 Karki, Nabin Raj Le, Thuy Cortes, Jorge Curr Oncol Rep Leukemia (A Aguayo, Section Editor) PURPOSE OF REVIEW: The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe infection and increased rates of mortality. There is paucity of information on how to modify care of leukemia patients in view of the COVID-19 risks and imposed restrictions. We review the available literature on the impact of COVID-19 on different types of leukemia patients and suggest general as well as disease-specific recommendations on care based on available evidence. RECENT FINDINGS: The COVID-19 infection impacts leukemia subtypes in variable ways and the standard treatments for leukemia have similarly, varying effects on the course of COVID-19 infection. Useful treatment strategies include deferring treatment when possible, use of less intensive regimens, outpatient targeted oral agents requiring minimal monitoring, and prioritization of curative or life-prolonging strategies. Reducing health care encounters, rational transfusion standards, just resource allocation, and pre-emptive advance care planning will serve the interests of leukemia patients. SUMMARY: Ad hoc modifications based on expert opinions and extrapolations of previous well-designed studies are the way forward to navigate the crisis. This should be supplanted with more rigorous prospective evidence. Springer US 2021-08-03 2021 /pmc/articles/PMC8330191/ /pubmed/34342734 http://dx.doi.org/10.1007/s11912-021-01111-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leukemia (A Aguayo, Section Editor) Karki, Nabin Raj Le, Thuy Cortes, Jorge The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title | The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title_full | The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title_fullStr | The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title_full_unstemmed | The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title_short | The Care of the Leukemic Patients in Times of SARS-CoV-2 |
title_sort | care of the leukemic patients in times of sars-cov-2 |
topic | Leukemia (A Aguayo, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330191/ https://www.ncbi.nlm.nih.gov/pubmed/34342734 http://dx.doi.org/10.1007/s11912-021-01111-0 |
work_keys_str_mv | AT karkinabinraj thecareoftheleukemicpatientsintimesofsarscov2 AT lethuy thecareoftheleukemicpatientsintimesofsarscov2 AT cortesjorge thecareoftheleukemicpatientsintimesofsarscov2 AT karkinabinraj careoftheleukemicpatientsintimesofsarscov2 AT lethuy careoftheleukemicpatientsintimesofsarscov2 AT cortesjorge careoftheleukemicpatientsintimesofsarscov2 |